Literature DB >> 22632938

Differential calcium handling in two canine models of right ventricular pressure overload.

Marc R Moon1, Abdulhameed Aziz, Anson M Lee, Cynthia J Moon, Shoichi Okada, Evelyn M Kanter, Kathryn A Yamada.   

Abstract

BACKGROUND: The purpose of this investigation was to characterize differential right atrial (RA) and ventricular (RV) molecular changes in Ca(2+)-handling proteins consequent to RV pressure overload and hypertrophy in two common, yet distinct models of pulmonary hypertension: dehydromonocrotaline (DMCT) toxicity and pulmonary artery (PA) banding.
METHODS: A total of 18 dogs underwent sternotomy in four groups: (1) DMCT toxicity (n = 5), (2) mild PA banding over 10 wk to match the RV pressure rise with DMCT (n = 5); (3) progressive PA banding to generate severe RV overload (n = 4); and (4) sternotomy only (n = 4).
RESULTS: In the right ventricle, with DMCT, there was no change in sarcoplasmic reticulum Ca(2+)-ATPase (SERCA) or phospholamban (PLB), but we saw a trend toward down-regulation of phosphorylated PLB at serine-16 (p[Ser-16]PLB) (P = 0.07). Similarly, with mild PA banding, there was no change in SERCA or PLB, but p(Ser-16)PLB was down-regulated by 74% (P < 0.001). With severe PA banding, there was no change in PLB, but SERCA fell by 57% and p(Ser-16)PLB fell by 67% (P < 0.001). In the right atrium, with DMCT, there were no significant changes. With both mild and severe PA banding, p(Ser-16)PLB fell (P < 0.001), but SERCA and PLB did not change.
CONCLUSIONS: Perturbations in Ca(2+)-handling proteins depend on the degree of RV pressure overload and the model used to mimic the RV effects of pulmonary hypertension. They are similar, but blunted, in the atrium compared with the ventricle.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22632938      PMCID: PMC3430801          DOI: 10.1016/j.jss.2012.04.066

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  50 in total

1.  Altered force-frequency response in non-failing hearts with decreased SERCA pump-level.

Authors:  Sabine Huke; Lynne H Liu; Danuta Biniakiewicz; William T Abraham; Muthu Periasamy
Journal:  Cardiovasc Res       Date:  2003-09-01       Impact factor: 10.787

2.  Validation of right and left ventricular conductance and echocardiography for cardiac function studies.

Authors:  M M Amirhamzeh; D A Dean; C X Jia; S E Cabreriza; O J Yano; D Burkhoff; H M Spotnitz
Journal:  Ann Thorac Surg       Date:  1996-10       Impact factor: 4.330

3.  Pharmacological strategies for improving diastolic dysfunction in the setting of chronic pulmonary hypertension.

Authors:  E P Chen; D M Craig; H B Bittner; R D Davis; P Van Trigt
Journal:  Circulation       Date:  1998-04-28       Impact factor: 29.690

4.  Differential changes in cardiac phospholamban and sarcoplasmic reticular Ca(2+)-ATPase protein levels. Effects on Ca2+ transport and mechanics in compensated pressure-overload hypertrophy and congestive heart failure.

Authors:  E Kiss; N A Ball; E G Kranias; R A Walsh
Journal:  Circ Res       Date:  1995-10       Impact factor: 17.367

5.  Cellular distribution of Ca2+ pumps and Ca2+ release channels in rat cardiac hypertrophy induced by aortic stenosis.

Authors:  M Anger; A M Lompré; O Vallot; F Marotte; L Rappaport; J L Samuel
Journal:  Circulation       Date:  1998-12-01       Impact factor: 29.690

6.  Production and reversibility of right ventricular hypertrophy and right heart failure in dogs.

Authors:  C M Hsieh; G J Mishkel; P F Cardoso; H Rakowski; S C Dunn; J Butany; R D Weisel; G A Patterson; J D Cooper
Journal:  Ann Thorac Surg       Date:  1992-07       Impact factor: 4.330

7.  Right ventricle-sparing heart transplantation effective against iatrogenic pulmonary hypertension.

Authors:  Constantinos Lovoulos; Shawn Tittle; Lee Goldstein; David J Austin; Simran Singh; Edward Rocco; James Keane; Ping Tang; Gary S Kopf; John A Elefteriades
Journal:  J Heart Lung Transplant       Date:  2004-02       Impact factor: 10.247

8.  Simple procedures for preparing putative toxic metabolites of pyrrolizidine alkaloids.

Authors:  A R Mattocks; R Jukes; J Brown
Journal:  Toxicon       Date:  1989       Impact factor: 3.033

9.  Pulmonary artery constriction produces a greater right ventricular dynamic afterload than lung microvascular injury in the open chest dog.

Authors:  J E Calvin; R W Baer; S A Glantz
Journal:  Circ Res       Date:  1985-01       Impact factor: 17.367

10.  Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium.

Authors:  G Hasenfuss; H Reinecke; R Studer; M Meyer; B Pieske; J Holtz; C Holubarsch; H Posival; H Just; H Drexler
Journal:  Circ Res       Date:  1994-09       Impact factor: 17.367

View more
  8 in total

1.  Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model.

Authors:  Jaume Aguero; Kiyotake Ishikawa; Lahouaria Hadri; Carlos Santos-Gallego; Kenneth Fish; Nadjib Hammoudi; Antoine Chaanine; Samantha Torquato; Charbel Naim; Borja Ibanez; Daniel Pereda; Ana García-Alvarez; Valentin Fuster; Partho P Sengupta; Jane A Leopold; Roger J Hajjar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-08-22       Impact factor: 4.733

Review 2.  Right Ventricular-Pulmonary Vascular Interactions.

Authors:  Diana M Tabima; Jennifer L Philip; Naomi C Chesler
Journal:  Physiology (Bethesda)       Date:  2017-09

3.  C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.

Authors:  Pan-Xia Wang; Zhuo-Ming Li; Si-Dong Cai; Jing-Yan Li; Ping He; Yi Huang; Guo-Shuai Feng; Hai-Bin Luo; Shao-Rui Chen; Pei-Qing Liu
Journal:  Acta Pharmacol Sin       Date:  2017-06-26       Impact factor: 6.150

Review 4.  World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology.

Authors:  Kurt W Prins; Thenappan Thenappan
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

5.  Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension.

Authors:  Kurt W Prins; Stephen L Archer; Marc Pritzker; Lauren Rose; E Kenneth Weir; Alok Sharma; Thenappan Thenappan
Journal:  J Heart Lung Transplant       Date:  2017-09-01       Impact factor: 10.247

6.  Protection against pressure overload-induced right heart failure by uncoupling protein 2 silencing.

Authors:  Azadeh Esfandiary; Hanna S Kutsche; Rolf Schreckenberg; Martin Weber; Oleg Pak; Baktybek Kojonazarov; Akylbek Sydykov; Christine Hirschhäuser; Annemarie Wolf; Daniela Haag; Matthias Hecker; Ludger Fink; Werner Seeger; Hossein A Ghofrani; Ralph T Schermuly; Norbert Weißmann; Rainer Schulz; Susanne Rohrbach; Ling Li; Natascha Sommer; Klaus-Dieter Schlüter
Journal:  Cardiovasc Res       Date:  2019-06-01       Impact factor: 10.787

7.  Protein changes contributing to right ventricular cardiomyocyte diastolic dysfunction in pulmonary arterial hypertension.

Authors:  Silvia Rain; Denielli da Silva Goncalves Bos; M Louis Handoko; Nico Westerhof; Ger Stienen; Coen Ottenheijm; Max Goebel; Peter Dorfmüller; Christophe Guignabert; Marc Humbert; Harm-Jan Bogaard; Cris Dos Remedios; Chandra Saripalli; Carlos G Hidalgo; Henk L Granzier; Anton Vonk-Noordegraaf; Jolanda van der Velden; Frances S de Man
Journal:  J Am Heart Assoc       Date:  2014-06-03       Impact factor: 5.501

8.  TSH inhibits SERCA2a and the PKA/PLN pathway in rat cardiomyocytes.

Authors:  Jiajia Dong; Cuixia Gao; Jing Liu; Yunshan Cao; Limin Tian
Journal:  Oncotarget       Date:  2016-06-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.